Lutetium-177 PSMA 靶向放射性治疗用于转移性去势抵抗性前列腺癌的采用：2016年至2020年德国全人口分析。
Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020.
发表日期：2023 Feb 24
作者：
Luka Flegar, Smita George Thoduka, Damiano Librizzi, Markus Luster, Aristeidis Zacharis, Hendrik Heers, Nicole Eisenmenger, Hojjat Ahmadzadehfar, Matthias Eiber, Wolfgang Weber, Christer Groeben, Johannes Huber
来源：
Eur J Nucl Med Mol I
摘要：
这项研究旨在调查在德国应用Lutetium-177 PSMA RLT治疗转移后去势抗雄激素难治性前列腺癌的采纳情况和当前趋势。我们分析了来自基于德国医院质量报告的报销.INFO工具的Lutetium-177 PSMA RLT数据（2016年至2020年），以及来自2006年至2020年全国德国医院结算数据库（Destatis）的开放性放射性核素与前列腺癌联合治疗的一般疗法数据。为了验证这些结算数据，我们包含了2016年至2020年两家参与机构的177Lu-PSMA RLT周期。为了检测随时间的趋势，我们应用了线性回归模型。从2006年至2020年，开放性放射性核素的一般治疗逐渐增加。我们共确认了12,553个177Lu-PSMA RLT周期。177Lu-PSMA RLT的数量从2016年的1026次治疗稳步增至2020年的3328次治疗（+ 每年576个RLT；p < 0.005）。2016年，25个核医学科室提供此项治疗，但到了2020年已有44个核医学科室提供此项治疗。2016年，16％的核医学科室（4/25）进行了100次以上的177Lu-PSMA RLT治疗，而到了2020年这一比例增长到了36％（16/44）（p < 0.005）。在2016年，88％（22/25）的177Lu-PSMA RLT治疗是在大学医院进行的，而这一比例在2020年降至了70％（31/44）。接受177Lu-PSMA RLT治疗的65岁以上患者比例从2016年的78％增至2020年的81％。最近几年，Lutetium-177 PSMA RLT治疗转移后去势抗雄激素难治性前列腺癌在德国得到了快速发展，为患者提供了另一种治疗选择。这一发展非常显著，因为Lutetium-177 PSMA RLT治疗已经获得欧洲药品管理局（EMA）的批准。© 2023. The Author(s).
This study is to investigate the adoption and current trends of Lutetium-177 PSMA RLT for mCRPC in Germany.We analyzed data from the reimbursement.INFO tool based on German hospitals' quality reports for Lutetium-177 PSMA RLT from 2016 to 2020 and from the nationwide German hospital billing database (Destatis) for general therapy with open radionuclides in combination with prostate cancer from 2006 to 2020. For validation of these billing data, we included the 177Lu-PSMA RLT cycles from two participating institutions from 2016 to 2020. For detection of trends over time we applied linear regression models.General therapy with open radionuclides increased from 2006 to 2020. We identified a total of 12,553 177Lu-PSMA RLT cycles. The number of 177Lu-PSMA RLTs steadily increased from a total of 1026 therapies in 2016 to 3328 therapies in 2020 (+ 576 RLT/year; p < 0.005). In 2016, 25 departments of nuclear medicine offered this treatment, which increased to 44 nuclear medicine departments in 2020. In 2016, 16% of nuclear medicine departments (4/25) performed more than 100 177Lu-PSMA RLTs, which increased to 36% (16/44) in 2020 (p < 0.005). In 2016, 88% (22/25) of 177Lu-PSMA RLTs were performed at a university hospital, which decreased to 70% (31/44) in 2020. The proportion of patients older than 65 years receiving 177Lu-PSMA RLT increased from 78% in 2016 to 81% in 2020.Treatment of mCRPC with 177Lu-PSMA RLT has been rapidly increasing in Germany in the recent years providing an additional therapy option. This development is remarkable, because of outstanding formal EMA approval.© 2023. The Author(s).